HIGHLANDS RANCH, Colo., July 07, 2021 (Globe NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a health-related technological innovation corporation targeted on acquiring and commercializing impressive diagnostic and remedy modalities for clients suffering from slumber-disordered respiration, such as mild-to-average obstructive sleep apnea (OSA), currently announced that the Corporation has unveiled new data from an impartial affected person survey relevant to its proprietary Vivos procedure for treating dental tissue anomalies and dentofacial malformations regarded to be related with OSA and other debilitating health conditions.
Important results consist of:
Virtually all (97 per cent) of individuals surveyed claimed that they experienced attained their wished-for consequence from the Vivos procedure for their OSA.
About half (63 p.c) of clients surveyed stated that they count on the assistance of their dentist to find a lasting alternative that addresses the root induce of their OSA.
Approximately a person-3rd (29 %) of people surveyed mentioned that they searched for non-surgical choices to recent standards of treatment for dealing with OSA.
“Patients are the best arbiter of whether a unique remedy modality has attained its preferred effects,” stated Kirk Huntsman, Vivos Chairman and CEO. “This survey reaffirms that sufferers are in dire need of a remedy for their OSA – 1 that is non-surgical, non-invasive, non-pharmaceutical and reduced-charge – and which is exactly the marketplace area of interest that the Vivos remedy fills. The simple fact that just about all people surveyed claimed that they experienced attained their desired remedy outcome is a powerful testimony about their clinical and cosmetic success. Our technology just operates.”
The wished-for result for numerous Vivos people is usually a considerable reduction in OSA and similar symptoms, as client pleasure and compliance fees with CPAP keep on being dismal. Some experiments display only 30 to 60 per cent CPAP adherence, and when still left untreated OSA’s underlying problems can turn into long-term comorbidities, some of which may possibly be lifetime threatening. In contrast, the Vivos therapy is generally done in around 12 to 24 months, after which most clients no more time demand ongoing intervention.
Commissioned by Vivos, The EyeDeas Enterprise, an impartial exploration company, designed the study and analyzed the details acquired from 123 anonymous people from 21 independent Vivos-skilled clinicians residing in several marketplaces in the U.S., in regards to the use and success of the Vivos treatment for addressing dental tissue anomalies and dentofacial malformations. Fieldwork was performed in June, 2021.
About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a professional medical technological know-how enterprise centered on building and commercializing impressive diagnostic and treatment modalities for adult clients struggling from sleep-disordered respiration, which includes obstructive snooze apnea (OSA). The Vivos treatment method for moderate-to-reasonable OSA consists of a customized oral appliance and protocols known as the Vivos Procedure. Vivos believes that its Vivos Process oral equipment technological know-how signifies the first clinically productive non-surgical, non-invasive, non-pharmaceutical and price tag-productive solution for individuals with mild-to-moderate OSA. Vivos also sells orthodontic appliances for grownups and youngsters. Vivos’ oral appliances have verified helpful in more than 17,000 sufferers globally by additional than 1,200 dentists. Combining systems and protocols that change the measurement, shape, and posture of the tissues of a patient’s higher airway, the Vivos Method opens airway place and could appreciably reduce signs and conditions connected with delicate-to-average OSA, these types of as reducing Apnea Hypopnea Index scores. Vivos also marketplaces and distributes VivosScore, run by the SleepImage diagnostic technologies for Property Rest Testing in older people and kids. The Vivos Built-in Observe (VIP) plan offers dentists education and other value-included products and services in link with using the Vivos Technique.
For extra information, check out www.vivoslife.com.
Cautionary Note With regards to Forward-Wanting Statements
This push release and statements of the Company’s administration manufactured in relationship therewith incorporate “forward-looking statements” (as defined in Area 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Trade Act of 1934, as amended) relating to long term functions, especially with respect to the public giving described herein. Phrases these kinds of as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and versions of such words and phrases and similar expressions are meant to detect forward-hunting statements. These statements require acknowledged and unidentified risks and are primarily based upon numerous assumptions and estimates, which are inherently matter to sizeable uncertainties and contingencies, several of which are past Vivos’ regulate. True success (together with the anticipated added benefits of the Company’s technology as explained herein) may vary materially from individuals expressed or implied by this kind of forward-hunting statements. Elements that could lead to genuine success to differ materially include, but are not confined to, the possibility things described in Vivos’ filings with the Securities and Trade Fee (“SEC”). Vivos’ filings can be attained free of demand on the SEC’s web-site at www.sec.gov. Besides to the extent essential by legislation, Vivos expressly disclaims any obligations or undertaking to launch publicly any updates or revisions to any forward-searching statements contained herein to replicate any improve in Vivos’ anticipations with respect thereto or any adjust in occasions, disorders, or circumstances on which any assertion is based mostly.
Investor Relations Contact:
Trader Relations Officer
Media Relations Speak to:
Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (212) 896-1231
[email protected] / [email protected]